Obsidian Therapeutics (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Obsidian Therapeutics

At Obsidian, our vision is pioneering engineered cell & gene therapies to deliver transformative outcomes for patients.

Founded 2015

Cambridge, United States 107 employees Unknown Total: $675.00M Biotechnology, Health Care +1

Obsidian Therapeutics, founded in 2015, is a **biotechnology** startup based in the United States, with a recent Series B investment of $115.00M on 09 September 2021. The company's focus lies in pioneering controllable cell and gene therapies to provide breakthrough solutions for patients suffering from intractable diseases. Obsidian's innovative approach involves utilizing their cytoDriveTM technology in cell and gene therapy products to regulate the expression of proteins, thereby enhancing therapeutic efficacy. Their lead program, cytoTIL15, aims to improve the effectiveness of TILs for a wider range of patients. Obsidian Therapeutics boasts a well-funded status with investments from prominent names such as **Amgen Ventures**, **Atlas Venture**, **RA Capital Management**, **The Column Group**, **Deep Track Capital**, **Logos Capital**, **Samsara BioCapital**, **TCG Crossover**, **Vertex Ventures HC**, and **Bristol-Myers Squibb**. This significant financial backing, along with a diverse and talented team, strategic partnerships with industry leaders, and a state-of-the-art laboratory facility in Bedford, positions the company to deliver on its ambitious goals. The company’s headquarters in the heart of Cambridge reflects its commitment to being at the forefront of innovation in the biotechnology and healthcare sectors. Obsidian also emphasizes creating an inclusive environment where each team member can thrive, while offering competitive salary and benefits, as well as the potential for employee ownership through stock options. With a strong vision and the necessary resources, Obsidian Therapeutics is poised to make significant advancements in addressing critical clinical needs and revolutionizing patient care with cutting-edge therapies.

Funding Stage	Amount	Investors	Lead Investors	Date
Private Placement Vc	••••••	-		01 Apr 2026
Series C	••••••	17	•••• ••••	01 Apr 2024
Series B	••••••	5		01 Sep 2021
Series A	••••••	6		01 Dec 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Private Placement Vc

••••••

01 Apr 2026

Series C

••••••

•••• ••••

01 Apr 2024

Series B

••••••

01 Sep 2021

Series A

••••••

01 Dec 2017

FAQ About Obsidian Therapeutics

At Obsidian, our vision is pioneering engineered cell & gene therapies to deliver transformative outcomes for patients.

Obsidian Therapeutics was founded in 2015.

Obsidian Therapeutics is headquartered in Cambridge, United States.

Obsidian Therapeutics operates in the following industries: Biotechnology, Health Care, Pharmaceutical.

Obsidian Therapeutics has approximately 107 employees.

Obsidian Therapeutics has completed 4 funding rounds, raising a total of $675.00M. The latest funding stage is Unknown.

Top alternatives and competitors to Obsidian Therapeutics include STRM.BIO, Taysha Gene Therapies, Genespire, Aruvant, Caribou Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Obsidian Therapeutics and STRM.BIO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Obsidian Therapeutics

General Information

Track Obsidian Therapeutics

Discover More

About Obsidian Therapeutics

Funding Rounds & Investors (4)

Obsidian Therapeutics Alternatives & Competitors

FAQ About Obsidian Therapeutics

Don't just browse. Track.